ALACHUA, FL--(Marketwire - January 30, 2009) - The Florida-based biotechnology firm Oragenics, Inc. (OTCBB: ORNI) announced today that it will not seek shareholder approval to change its corporate name to ONI BioPharma Inc., but will continue to be registered as Oragenics, Inc. In commenting on this decision, Stanley Stein, Oragenics’ CEO, stated, “The Oragenics name is well recognized by the investment community and the decision not to seek a name change was taken in order to eliminate any potential confusion in the marketplace regarding the identity of our Company. The Company’s common stock will continue trading under the Company’s currently registered name of Oragenics, Inc.”
About Oragenics
Oragenics, Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville.
CONTACT:
Linda Loren
Marketing Director
Oragenics, Inc.
727-456-0029
Email Contact